ADMINISTRATION The Office of Translational Research (OTR), under the leadership of CCSG deputy director Dr. Robert Bast, coordinates and implements all administrative functions related to the CCSG. Dr. Bast has a dual reporting relationship, reporting directly to Dr. Giulio Draetta, chief scientific officer, and to Dr. Peter Pisters, MD Anderson president and CCSG PI for matters relating to the CCSG. Dr. Bast's staff provides administrative support and financial, scientific, and technical oversight for the CCSG programs; for all institutional shared resources, including CCSG core facilities; and for all other CCSG components, including Clinical Protocol and Data Management (CPDM), the Protocol Review and Monitoring System (PRMS), Community Outreach and Engagement, Career Enhancement and Related Activities, Development Funds, Senior Leadership, Planning and Evaluation, and CCSG administrative supplements. OTR staff serve on many of MD Anderson's advisory and oversight committees, including MD Anderson's Moon Shot Operations and Executive Committee and committees responsible for capital equipment allocation, oversight of research data storage, and financial controls. Administrative support is provided in the following areas: 1) business operations and financial management of shared resources; 2) central organization and coordination for the scientific and technical aspects of shared resource operations; 3) facilitation of programmatic interactions and engagement; 4) facilitation of communication between center director, program leaders, shared resource directors, and program members; 5) development, management, and maintenance of databases for program funding, program membership, program member publications, program member biographical information, and shared resource utilization; 6) allocation and monitoring of the use of CCSG development funds; 7) coordination and writing of CCSG progress reports and competitive renewal applications; and 8) organization of CCSG Executive Committee and annual External Advisory Board meetings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-44
Application #
9997791
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360
Ellrott, Kyle; Bailey, Matthew H; Saksena, Gordon et al. (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6:271-281.e7
White, Matthew C; Schroeder, Rebecca D; Zhu, Keyi et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene 37:4413-4427
Abaza, Yasmin; Hidalgo-Lopez, Juliana E; Verstovsek, Srdan et al. (2018) Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85
McGrail, Daniel J; Federico, Lorenzo; Li, Yongsheng et al. (2018) Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9:1317
Li, Carrie J; Jiang, Changying; Liu, Yang et al. (2018) Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther :
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Raber, Benjamin; Bea, Vivian J; Bedrosian, Isabelle (2018) How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26:281-288
Li, Roger; Metcalfe, Michael J; Ferguson 3rd, James E et al. (2018) Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121:244-251

Showing the most recent 10 out of 12418 publications